LEI105 is a highly selective and reversible diacylglycerol lipase ( DAGL ) inhibitor that exhibits significant inhibitory activity against human DAGLα and DAGLβ (e.g., the pIC 50 value against human DAGLα is 8.5, and the IC 50 against human DAGLβ is 32 nM). LEI105 effectively reduces intracellular 2-arachidonoylglycerol levels and inhibits CB1 receptor-mediated short-term synaptic plasticity. LEI105 can be used to investigate the on-demand biosynthesis of 2-AG in retrograde signaling.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > DAGL
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。